US 12233051
Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase
granted A61KA61K31/427A61K31/4439
Quick answer
US patent 12233051 (Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/427, A61K31/4439, A61K31/506